HBC Hofseth Biocare

Hofseth Biocare ASA: DISCLOSURE OF VOTING PROXIES

Hofseth Biocare ASA: DISCLOSURE OF VOTING PROXIES

Reference is made to the notice from Hofseth BioCare ASA (the "Company") for an annual general meeting to be held on 28 April 2023 (the "AGM").

Torill Standal Eliassen, board member of the Company, has received proxies to vote for 128,476,755 shares in the Company at the AGM, corresponding to 32.52% of the outstanding shares and votes. Torill Standal Eliassen does not own any shares in the Company.

The voting proxies lapse automatically after the AGM has been held.

This notification is made with reference to section 4-3 of the Norwegian Securities Trading Act and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jon Olav Ødegård, CEO at HBC

Phone:

E-mail:



EN
28/04/2023

Underlying

HBCHofseth Biocare

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: HBC publishes paradigm-changing clinical trial re...

Hofseth BioCare ASA: HBC publishes paradigm-changing clinical trial results of OmeGo full spectrum omegas HBC announces the publication of its head-to-head clinical trial results with its patented, full spectrum omegas brand, OmeGo®. The trial showed that OmeGo® increased the Omega 3 Index (O3I) by over 70% after 14 weeks, over and above a popular omega-3 supplement brand. It was also markedly more effective at reducing inflammatory markers (hsCRP, TNFa and IL-6) which are closely related to the development of ill health. The omega-3 index (O3I) assesses the level of EPA and DHA in red blo...

April 14, 2026 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: HBC ANNUAL REPORT 2025

Hofseth BioCare ASA: HBC ANNUAL REPORT 2025 The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2025, and HBC has today published the Annual Report and Sustainability Report for 2025. In October 2025, the Company announced a successful placing of new ordinary shares with gross proceeds of NOK 158 million. As of the date of this Annual report, the Company has yet to receive all share deposits and has therefore not completed the transaction. The primary cause of the delay is stated to be of a technical and legal nature relating to the main investor ...

March 27, 2026 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: FOURTH QUARTER 2025 FINANCIAL REPORT

Hofseth BioCare ASA: FOURTH QUARTER 2025 FINANCIAL REPORT HBC recorded total operating revenues of NOK 72.2 million in the fourth quarter of 2025, compared to NOK 64.9 million in the same period last year. Net operating revenues were NOK 71.1 million, up from NOK 64.9 million in Q4 2024. Full year 2025, total operating revenues amounted to NOK 256.3 million (265.5). Total operating revenue in 2024 included NOK 8.1 million of gain on sale of assets. EBITDA for the quarter was negative NOK 26.5 million, compared to negative NOK 26.1 million in Q4 2024. For full year 2025, EBITDA was negative...

February 13, 2026 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Notification of major shareholdings

Notification of major shareholdings Effective February 9, 2026, the “Bonafide Investment Fund – Best Catches I” made a subscription in kind to the “Bonafide Investment Fund – HBC II”. Following the subscription in kind, the Bonafide Investment Fund – Best Catches I no longer holds shares in Hofseth Biocare ASA. According to the information published on the website of the Oslo Stock Exchange, the total number of outstanding shares of Hofseth Biocare ASA currently amounts to 395,081,030. Based on this figure, IFM Independent Fund Management AG will hold a total of 16.62% of the voting rights...

February 11, 2026 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: Cancellation of Subsequent Offering – Update on c...

Hofseth BioCare ASA: Cancellation of Subsequent Offering – Update on completion of Private Placement NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to previous announcements by Hofseth BioCare ASA (the "Company") regarding a subsequent offering with gross proceeds of up to approx. NOK 30,000,000 throug...

December 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch